61 results about "S100A8" patented technology

The invention provides an anti-S100A8 / A9 antibody and application of the anti-S100A8 / A9 antibody. The antibody or the antigen binding fragment and the mutant thereof provided by the invention can block the biological function of S100A8 / A9. The antibody or the antigen binding fragment provided by the invention is expected to be developed into a clinical drug, so that the cardiac infarction area of an AMI patient is reduced, the occurrence of heart failure is reduced, the AMI patient is benefited for the whole life, and the antibody or the antigen binding fragment has important clinical significance and development value.

The invention relates to application of seroalarm as a biomarker in predicting the curative effect of a JAK inhibitor on alopecia areata. Particularly, S100A8 / A9 and S100B are the most preferable biomarkers, and the curative effect of the JAK inhibitor on alopecia areata can be effectively predicted by detecting the concentration of the biomarkers in the serum of an alopecia areata patient, so that valuable reference is provided for selection of an alopecia areata treatment scheme.

The invention relates to a biomarker combination for clinical benefit of non-small cell lung cancer immunotherapy and application of the biomarker combination. The biomarker for predicting the clinical benefit of the non-small cell lung cancer immunotherapy comprises an immune globulin kappa light chain variable region 1-27 (IGKV1-27), a human leukocyte antigen H (HLA-H), an S100 calcium binding protein A8 (S100A8), a chromogranin A (CHGA), an elastin (ELN) and a nephronectin (NPNT). The biomarkers for predicting the clinical benefit of the immunotherapy of the non-small cell lung cancer can be detected, and the clinical benefit effect of the immunotherapy of the non-small cell lung cancer of a patient is judged by the markers.

The invention discloses an application of S100A8 / A9 in evaluating the severity of infectious diseases. Specifically disclosed is the use of a biomarker (S100A8 / A9) and / or a substance for detecting the biomarker in the preparation of a product for evaluating the severity of infectious diseases. By detecting the level of S100A8 / A9 in serum or plasma, the severity of infectious diseases is rapidly and accurately evaluated, the evaluation process is simplified, the accuracy is improved, and the kit is suitable for various infectious diseases. The biomarker is high in sensitivity and good in specificity, decision support can be provided for clinicians by evaluating the severity of the illness state, a treatment scheme can be provided for patients more accurately, the treatment effect and the living quality of the patients can be improved, meanwhile, optimal disease management is achieved, the medical burden on families and the society of the patients is relieved, and the application prospect is wide. Good and wide clinical application values are realized.

The application provides a group of small interfering RNAs (siRNAs) targeting pyroptosis-related inflammatory reaction genes and application thereof. The pyroptosis-related inflammatory reaction genes include IL1A, IL1B, IL6, HMGB1, S100A8, S100A9 and BACH1. The application designs and synthesizes specific siRNA sequences for the above genes, and verifies that the siRNAs can efficiently and specifically inhibit the mRNA expression level of the corresponding genes through cell transfection and real-time fluorescent quantitative PCR. The application also provides a composition containing the siRNAs, a pharmaceutical composition and application thereof in the preparation of a drug for treating diseases mediated by pyroptosis-related inflammatory reaction genes (especially inflammatory diseases). The siRNAs and the composition thereof provide a new effective strategy for treating diseases related to excessive activation of pyroptosis-related inflammatory reactions, and have a wide application prospect.

The invention belongs to the field of medicine, and relates to a construction method of a pneumonia severity prediction model and the prediction model.The construction method comprises the steps that 1, a serum sample of a patient infected by mycoplasma pneumonia is obtained; 2) detecting the content of S100A8 / A9 protein in the serum sample; 3) establishing a data set according to the patient infected by mycoplasma pneumonia, wherein the data set comprises a training set and a verification set; 4) constructing a regression model for the content of the S100A8 / A9 protein by adopting a lasso regression mode; and 5) training the regression model by using the training set to obtain a pneumonia severity prediction model. The invention provides the construction method of the pneumonia severity prediction model which has good prediction performance and good clinical applicability and can improve the accuracy of risk stratification of mycoplasma pneumonia patients, and the prediction model.

The present invention relates to the use of an s100a8 / a9 and complement 3 inhibitor in the preparation of a drug for treating or preventing cachexia. The treatment or prevention of cachexia comprises increasing the body weight, lean body mass and fat mass, and increasing food intake in a cachectic subject, or preventing fat mass consumption, slowing the rate of body weight loss, the rate of fat mass loss and the rate of lean body mass loss, counteracting anorexia, muscle strength loss, fatigue and body weight loss, or improving abnormal biochemical results. Provided is a new understanding for the mechanism of energy balance regulation in cancer cachexia, with an emphasis on the effects of S100a8 / a9 and C3 in cancer cachexia. The inhibition of S100a8 / a9 and complement 3 can promote fat recovery and increase food intake. Particularly, it is verified that an S100a8 / a9 inhibitor can prevent body weight loss, especially adipose tissue loss, in a cachectic subject, and significantly increases food intake in the subject.

The application relates to the field of biological medicine, and discloses application of folic acid in prevention, diagnosis and treatment of genetic, infectious or allergic diseases. The application finds that the folic acid can achieve the prevention and treatment effects on the genetic, infectious or allergic diseases by improving inflammation, regulating iron ion metabolism, correcting intestinal flora disorder, reducing liver / intestinal tissue damage, inhibiting expression of inflammatory factors and promoting expression of Nox2. Meanwhile, the application provides application of one or more of the folic acid, S100a8, S100a9, Nox2 and IFN-gamma as a diagnostic or auxiliary diagnostic marker of biliary atresia. Meanwhile, the application provides the folic acid or a derivative thereof, which is prepared into food, a nutritional preparation or a medicine and applied to children or adults, so as to achieve the purposes of preventing and treating biliary atresia, cholangitis, jaundice, infectious diseases, intestinal diseases and diseases caused by abnormal folic acid metabolism.

The application discloses a use of ubiquitination as a marker of systemic juvenile idiopathic arthritis, and relates to the technical field of biomedicine. The marker provided by the application is a gene combination of at least two genes in ubiquitination which participates in the occurrence of sJIA inflammation by mediating NLRs pathway; the ubiquitination includes HP, S100A9, S100A12, S100A8, IL6, CFH and UBE2D1; and the gene combination at least includes a combination of any one of HP and IL6 and UBE2D1. The application constructs a joint detection scheme of UBE2D1 and inflammatory factors, chemotactic factors or immune-related molecules, and can make up for the problems of insufficient stability or limited specificity of a single index to some extent, thereby improving the auxiliary diagnosis efficiency on sJIA. Meanwhile, the detection object involved in the application is clear, the detection mode is feasible, the detection can be carried out based on a blood sample, and the application has the advantages of relatively simple operation, strong clinical implementability, convenience for development into a detection kit, a detection chip or a matching detection reagent.

The invention belongs to the technical field of bioengineering, and particularly relates to a preparation method and application of a calprotectin S100A8 / A9 dimer mouse monoclonal antibody, the monoclonal antibody comprises a heavy chain variable region and a light chain variable region; the heavy chain variable region comprises any one of amino acid sequences as shown in SEQ ID NO.22-24; the heavy chain variable region comprises any one of amino acid sequences as shown in SEQ ID NO.22-24; the light chain variable region comprises an amino acid sequence as shown in SEQ ID NO. 28-30. According to the present invention, the S100A8 / A9 heterodimer protein with biological activity and immunostimulation function is prepared, the protein is used to immunize mice, the specific gene engineering antibody of the S100A8 / A9 heterodimer protein is prepared, the antibody pair with high sensitivity is screened, and the calprotectin S100A8 / A9 double-antibody sandwich enzyme-linked immunosorbent assay method is preliminarily developed;

The invention discloses a method for analyzing serum differential expression protein characteristics of an AQP4-IgG positive NMOSD patient, and relates to the technical field of differential expression protein characteristic analysis, and the method comprises the following steps: S1, collecting a serum sample of a to-be-detected subject; s2, carrying out protein detection on the serum sample to obtain expression level data of at least one or more of PRDX2, CLU, ECM1, CFD, GPI and S100A8, wherein the expression level data is one or more of PRDX2, CLU, ECM1, CFD, GPI and S100A8; s3, carrying out comparative analysis on the expression level of the serum protein and a pre-established AQP4-IgG positive NMOSD serum protein expression characteristic reference standard; according to the method for auxiliary diagnosis of the AQP4-IgG positive neuromyelitis optica pedigree disease provided by the invention, a judgment mode capable of reflecting molecular characteristics of the AQP4-IgG positive neuromyelitis optica pedigree disease is constructed by carrying out conjoint analysis on various serum protein expression characteristics related to immunoregulation, inflammatory response, complement activation and metabolism; therefore, the problem of insufficient detection stability of a single biomarker is avoided.

This invention relates to the use of S100a8 / a9 and complement 3 inhibitors in the preparation of medicaments for the treatment or prevention of cachexia, wherein the treatment or prevention of cachexia involves increasing the body weight, lean body mass, fat mass, and food intake of cachectic subjects, or preventing fat loss, slowing the rate of weight loss, slowing the rate of fat mass loss, slowing the rate of lean body mass loss, resisting anorexia, resisting muscle weakness, resisting fatigue, resisting weight loss, and improving abnormal biochemical results. This invention provides a new understanding of the mechanism of energy balance regulation in cancer cachexia, focusing on the roles of S100a8 / a9 and C3 in cancer cachexia. This invention finds that inhibiting S100a8 / a9 and complement 3 can promote fat recovery and increase food intake. In particular, it demonstrates that S100a8 / a9 inhibitors can prevent the loss of body weight, especially adipose tissue, in cachectic subjects and significantly increase their food intake.

The invention relates to an anti-S100A8 / A9 monoclonal antibody for treating severe acute pancreatitis and application of the anti-S100A8 / A9 monoclonal antibody. Specifically, the invention provides a nano antibody combined with dimers of S100A8 and S100A9 or an antigen binding fragment of the nano antibody, and provides application of the nano antibody or the antigen binding fragment in treatment of pancreatitis. Meanwhile, the invention also provides an application of the antibody combined with the dimers of the S100A8 and the S100A9 or the antigen binding fragment of the antibody in treatment of pancreatitis. The antibody provided by the invention has a good treatment effect on severe acute pancreatitis, and has important clinical significance and development value.

An isolated or purified antisense oligomer (ASO) for modifying pre-mRNA splicing or mRNA translation in one or more of the following proteins encoded by the respective gene transcript or part thereof S100A8; S100A9; and / or IL1RL2.

The present invention relates to the use of urine protein as a diagnostic marker for primary biliary cholangitis (PBC). The urine protein includes one or a combination of osteopontin (OPN), receptor activity-modifying protein 3 (RAMP3), and calcium-binding protein (S100A8). This application uses urine as a non-invasive test sample, making it more readily accepted by patients than blood. It is of great significance for the early, non-invasive diagnosis of PBC patients.

To provide a biomarker for determining the severity and / or activity of atopic dermatitis.SOLUTION: Disclosed is a biomarker comprising at least one selected from the group consisting of S100A6, S100A8, Lipocapin-2, Fibrinogen, Calcitonin, VWF, Cardiotrophin-1, CystatinA, FGF-18, and Ubiquitin + 1.SELECTED DRAWING: None

The present invention refers to inhibitors of the S100 calcium- binding protein A9 (S100A9) / S100A8 – Toll Like Receptor 4(TLR4) dimer-receptor axis for use in the treatment of Heart Failure with preserved Ejection Fraction (HFpEF). The present invention further refers to pharmaceutical formulations comprising the said inhibitors. The present invention's use of compounds and pharmaceutical formulations may be advantageously employed in HFpEF by attenuating the deleterious effect on endothelial function and prevention of inflammation, production of reactive oxygen species, apoptosis, senescence and pro-fibrotic phenotype.

The invention discloses a drug-loaded gel and an application thereof in preparation of a drug for repairing endometrial injury, and belongs to the field of biological medicine, the drug-loaded gel is composed of poloxamer P407 and S100A8, the drug-loaded gel is prepared from PBS, and the ratio of the poloxamer 407 to the S100A8 to the PBS is 0.2 g: 5 [mu] g: 1 mL. According to the invention, poloxamer 407 hydrogel is used for carrying S100A8 to prepare a drug-loaded gel, and by constructing a rat endometrial injury model and applying the drug-loaded gel for treatment, the result shows that the drug-loaded gel can maintain the intact degree of endometrial epithelium and increase the levels of molecular indexes such as Ki-67, Claudin-1 and ZO-1 related to endometrial epithelium repair, so that the drug-loaded gel can be used for treating endometrial epithelium. Therefore, the endometrial injury of the rat is remarkably relieved, and a new idea is provided for repairing the endometrial injury.

The invention relates to an anti-S100A8 / A9 monoclonal antibody for treating sepsis and application of the anti-S100A8 / A9 monoclonal antibody. Specifically, the invention provides an application of an antibody combined with dimers of S100A8 and S100A9 or an antigen binding fragment of the antibody in treatment of sepsis, liver injury and lung injury. The antibody provided by the invention has a relatively good treatment effect on sepsis and liver injury and lung injury caused by sepsis, and has important clinical significance and development value.

This disclosure describes compositions and methods involved in tumor suppression and inhibiting infection of cells by pathogens. Generally, the compositions include an mRNA cargo that can provide a therapeutic benefit after being introduced into an epithelial cell. In some cases, the mRNA can encode a polypeptide. In some cases, the polypeptide can suppress epithelial cell proliferation. In other embodiments, the polypeptide can be involved in innate immunity. In various embodiments, the polypeptide can include cathelicin antimicrobial protein (CAMP), calprotectin, S100A8, S100A9, a β-defensin, S100A7, secretory leukocyte inhibitor, lipocalin 2, or lysozyme. In some embodiments, the mRNA can include a stabilizing moiety such as, for example, a 5′ cap or a 3′ extension.

The invention relates to application of seroalarm as a biomarker in predicting the curative effect of a JAK inhibitor on alopecia areata. Particularly, S100A8 / A9 and S100B are the most preferable biomarkers, and the curative effect of the JAK inhibitor on alopecia areata can be effectively predicted by detecting the concentration of the biomarkers in the serum of an alopecia areata patient, so that valuable reference is provided for selection of an alopecia areata treatment scheme.

An in vitro method for assessing or predicting the response of a human patient to periodontal disease treatment is disclosed. The method is based on the insight that biomarker proteins are determined. Thus, in a saliva sample of a patient, the concentration of a specific combination of proteins is measured. One such combination is hemoglobin subunit delta (Hb-delta) and pyruvate kinase (PK). Another combination is at least two of alpha-1-acid glycoprotein (A1AGP), pyruvate kinase (PK), and matrix metallopeptidase-8 (MMP-8), and keratin-4 (K-4). A third combination is alpha-1-acid glycoprotein (A1AGP), pyruvate kinase (PK), and S100 calcium-binding protein A8 (S100A8). Based on the measured concentrations, at least one value is determined that reflects the joint concentration of this proteins. The at least one value can be indicative of the likelihood that the human patient has or will successfully treat periodontitis. The at least one value can be compared to at least one threshold value that reflects the joint concentration in the same way that is associated with successful treatment of periodontitis. This comparison allows to assess whether the test value is an indication of the periodontal treatment status of the patient.

The invention belongs to the technical field of genetic engineering, and relates to codon-optimized calprotectin, a nucleic acid molecule and a preparation method and application of the codon-optimized calprotectin and the nucleic acid molecule. Aiming at the technical problem that in the prior art, when calprotectin is produced by utilizing engineering bacteria, a double-vector expression strategy is generally adopted for S100A8 and S100A9, so that the biological activity and stability of expression are poor, the invention provides a codon-optimized calprotectin nucleic acid molecule, and a nucleic acid molecule for coding S100A8 has a nucleotide sequence shown as SEQ ID NO: 3; the nucleic acid molecule for coding the S100A9 has a nucleotide sequence as shown in SEQ ID NO: 4, and the purity, concentration, yield, activity and ED50 of the prepared calprotectin are improved compared with those in the prior art. The invention further provides a preparation method of the calprotectin, target protein is expressed and purified by using the calprotectin nucleic acid molecule, the recombinant expression vector containing the calprotectin nucleic acid molecule and / or the recombinant genetic engineering cell, the cost is low, the method is suitable for large-scale production, and the protein is high in biological activity and good in stability.

Disclosed herein are compositions and methods for predicting response to a BET inhibitor based on the expression level of S100A8 and ER stress response genes. Also disclosed are methods of sensitising subjects found to be resistant using one or more of a S100A8 inhibitor, an ER stress inducing agent and / or a c-KIT inhibitor.

The present application provides an anti-S100A8 / A9 antibody and use thereof. The antibody or antigen-binding fragment thereof, and mutants thereof, provided by the present application, can block the biological functions of S100A8 / A9. The antibody or antigen-binding fragment thereof provided by the present application is expected to be developed into a clinical drug, with the aim of reducing the myocardial infarct size in acute myocardial infarction (AMI) patients, lowering the incidence of heart failure, and providing lifelong benefit to the AMI patients. The present application has significant clinical implications and development value.

Disclosed is an in vitro method for assessing whether a human patient suffering from periodontitis has mild periodontitis or advanced periodontitis. The method is based on the insight to determine a selection of two biomarker proteins. Accordingly, in a sample of saliva a patient suffering from periodontitis, the concentrations are measured of the proteins Pyruvate Kinase (PK) and at least one of Matrix metalloproteinase-9 (MMP9), S100 calcium-binding protein A8 (S100A8), and Hemoglobin subunit beta (Hb-beta); or of the proteins Matrix metalloproteinase-9 (MMP9) and at least one of S 100 calcium-binding protein A8 (S100A8) and S100 calcium-binding protein A9 (S100A9). Based on the concentrations as measured, a value is determined reflecting the joint concentrations for said proteins. This value is compared with a threshold value reflecting in the same manner the joint concentrations associated with advanced periodontitis. The comparison allows assessing whether the testing value is indicative of the presence of advanced periodontitis or of mild periodontitis in said patient. Thereby, typically, a testing value reflecting a joint concentration below the joint concentration reflected by the threshold value is indicative for mild periodontitis in said patient, and a testing value reflecting a joint concentration at or above the joint concentration reflected by the threshold value, is indicative for advanced periodontitis in said patient.

A use of S100A8 / A9 in assessing the severity of infectious diseases, and a use of a biomarker (S100A8 / A9) and / or a substance for detecting the biomarker in the preparation of a product for assessing the severity of infectious diseases. By detecting the level of S100A8 / A9 in serum or plasma, the severity of infectious diseases is rapidly and accurately assessed, thereby simplifying an assessment process and improving accuracy, and the present invention is suitable for various infectious diseases. The biomarker exhibits high sensitivity and good specificity; by assessing the severity of diseases, the present invention provides decision-making support for clinicians, and provides more precise treatment schemes for patients, thereby improving therapeutic efficacy and the quality of life of the patients; and additionally, optimal disease management is achieved, the medical burden on patients' families and society is reduced, and the present invention has favorable and broad clinical application value.

The present application relates to the field of biotechnology, in particular to the use of CD300LD inhibitors in the preparation of products for preventing, diagnosing or treating tumors, CD300LD inhibitors regulate the migration and function of PMN-MDSC cells by regulating S100A8 / A9 in its downstream signaling pathway, and play an important role in the establishment of tumor microenvironment; CD300LD inhibitors can effectively inhibit the development of various solid tumor mouse models, and have significant anti-tumor synergistic effect with PD1 antibodies; in the stage when the tumor has been established, the application of CD300LD inhibitors can significantly inhibit the development of tumors. The present application provides a new target and idea for tumor immunotherapy.

The invention provides application of multiple plasma biomarkers in preparation of aortic dissection combined diagnosis products. The application comprises one or more of the following applications: 1) application in preparation of aortic dissection diagnosis products; 2) application in preparation of products for screening aortic dissection; 3) application in preparation of products for evaluating the risk of aortic dissection; the biomarker composition comprises a BPI protein and an S100A8 / A9 protein in blood plasma. A plurality of biomarkers are jointly applied to aortic dissection diagnosis, so that the sensitivity, the specificity and the diagnosis rate of aortic dissection diagnosis can be remarkably improved, and rapid, non-invasive and low-cost early diagnosis is realized.

The invention belongs to the technical field of biological medicine and molecular biology, and provides application of S100A8 in preparation of a medicine for preventing / treating bladder infection after spinal cord injury. The S100A8 can be used as a prevention target of bladder infection after potential spinal cord injury, and after the S100A8 is perfused into the bladder, the colony count of the bladder tissue is obviously reduced, so that the S100A8 has an infection prevention effect; meanwhile, the damage repair capacity of the bladder epithelium is remarkably improved, the compound can be used as a prevention / treatment target spot for preventing bladder infection after spinal cord injury, and a new thought is provided for clinical prevention and treatment of bladder infection after spinal cord injury.